ARTICLE | Clinical News
Intranasal calcitonin: Began Phase II/III trial
January 10, 2000 8:00 AM UTC
Unigene Inc. (UGNE), Fairfield, N.J. Product: Intranasal calcitonin Business: Musculoskeletal Therapeutic category: Drug delivery, Hormone replacement Target: Osteoclasts Description: Osteoclast inhib...